Athersys (ATHX) Competitors

Athersys (NASDAQ:ATHX) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, community ranking, profitability, earnings and analyst recommendations.

Does the MarketBeat Community prefer ATHX or ENVB?

Athersys received 359 more outperform votes than Enveric Biosciences when rated by MarketBeat users. However, 60.00% of users gave Enveric Biosciences an outperform vote while only 56.15% of users gave Athersys an outperform vote.

Company	Underperform	Outperform
Athersys	Outperform Votes 365 56.15%	Underperform Votes 285 43.85%
Enveric Biosciences	Outperform Votes 6 60.00%	Underperform Votes 4 40.00%

Do analysts prefer ATHX or ENVB?

Enveric Biosciences has a consensus target price of $10.00, suggesting a potential upside of 743.88%. Given Enveric Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Enveric Biosciences is more favorable than Athersys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Enveric Biosciences	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor ATHX or ENVB?

In the previous week, Enveric Biosciences had 3 more articles in the media than Athersys. MarketBeat recorded 3 mentions for Enveric Biosciences and 0 mentions for Athersys. Enveric Biosciences' average media sentiment score of 0.29 beat Athersys' score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Athersys	Neutral
Enveric Biosciences	Neutral

Is ATHX or ENVB more profitable?

Athersys' return on equity of 0.00% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Enveric Biosciences	N/A	-221.54%	-164.32%

Which has more risk & volatility, ATHX or ENVB?

Athersys has a beta of -0.9, meaning that its share price is 190% less volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Do institutionals and insiders believe in ATHX or ENVB?

19.4% of Athersys shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 0.0% of Athersys shares are owned by insiders. Comparatively, 1.1% of Enveric Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has better earnings and valuation, ATHX or ENVB?

Enveric Biosciences has lower revenue, but higher earnings than Athersys. Enveric Biosciences is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Enveric Biosciences	N/A	N/A	-$17.29M	-$38.38	-0.03

Summary

Enveric Biosciences beats Athersys on 10 of the 16 factors compared between the two stocks.